TAILOR-PCI Fails To Meet Goal, Provides Insight on Genotype-Guided Therapy
Data presented at ACC.20/WCC is shedding light on the impact of genotype-guided antiplatelet therapy in patients undergoing PCI for ACS or CAD.
Vericiguat Significantly Reduces Heart Failure Hospitalization, Death
New VICTORIA findings show the novel therapy may reduce risk of severe outcomes among high-risk patients with HFrEF.
ACC House Call: Deepak Bhatt, MD, on COVID-19
Discussing the impact of COVID-19 on ACC.20/WCCardio and the cardiology community throughout the country.
Deepak Bhatt, MD: Choosing Adjunct Therapies for Lowering LDL-C
Discussing how approval of bempedoic acid impacts the role of PCSK9 inhibitors for lowering LDL-C.
PCSK9 Use Remains Limited Among Familial Hypercholesterolemia Patients
New findings show eligible men and minority group patients are less likely to receive a fill for the novel drug class.
ACC House Call: Conscious Sedation for TAVR Procedure
A new study assesses the preference and benefit of conscious sedation versus general anesthesia in TAVR patients.
Add-On Evolocumab Sustains LDL-C Reduction in CAD Patients
An open-label extension of GLAGOV shows the monoclonal antibody plus statin therapy is not associated with any new safety concerns.
Mental Stress Increases Risk of Secondary Cardiovascular Events
A new Emory University study sheds light on the relationship between mental and cardiovascular health.
Deepak Bhatt, MD: Ticagrelor and Major Adverse Limb Events
A special edition ACC House Call with Deepak Bhatt, MD, to discuss the results of a meta-analysis looking at ticagrelor and MALE from 2 clinical trials.
ACC House Call: Usability of Novel VTE Risk Score with Deepak Bhatt, MD
A discussion on a study from ACC.20 examining use of a novel genetic risk score to predict VTE in patients with cardiometabolic disease.
ACC House Call: The Decision to Go Virtual
An ACC board member explains the major cardiology college's decision to move the meeting online during the COVID-19 pandemic.
Roxana Mehran, MD: ACC 2020 Preview
The Mount Sinai expert and ACC late-breaking presentation panelist highlights her most anticipated trial data and discussions in the upcoming meeting.
ACC House Call: Featured Topics with Deepak Bhatt, MD
Executive Director of Interventional Cardiovascular Programs at Brigham and Women's discusses some research he took part in being presented at this year's conference.
Normal Sleep Patterns Reduce Arterial Thickness
In a new study, investigators discover 7-8 hours as the optimal sleep duration for reducing the risk of strokes and heart disease.
ACC House Call: Where Will SGLT-2 Inhibitors Go Now?
Muthiah Vaduganathan, MD, MPH, discusses how research of the add-on drug class will continue to evolve into 2021.
Low Birth Weight Could Indicate Increased Heart Failure Risk in Mothers
New data from ACC.20/WCC indicates low birth weight in infants could indicate mothers who are at increased risk of heart failure later in life.
ACC House Call: Future TAVR Advances
How will heart valve options refine and progress over the coming year?
ACC House Call: Current SGLT-2 Inhibitor Standing
A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.
Increased Protein Intake Could Reduce Atrial Fibrillation In Older Women
New research presented at ACC.20/WCC suggests increased protein intake could reduce the risk of atrial fibrillation in older women up to 8%.
ACC House Call: Align TAVR with Gilbert Tang, MD
The author of the first systematic evaluation of commissural alignment in TAVR shares his team's findings.
US Adult E-Cigarette Use Climbing, Despite Cardiology Health Concerns
About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.
Statins Could Reduce Cardiotoxicity, Heart Failure from Chemotherapy
New research from ACC.20/WCC suggests taking statins before initiating chemotherapy with anthracycline or trastuzumab could reduce treatment-associated cardiotoxicity.
Specific Cancer Types May Carry Increased Risk for Atrial Fibrillation
New data from ACC.20/WCC is revealing more about the risk of AF associated with various cancer types.
Adam DeVore, MD: Confidently Treating HF with Sacubitril/Valsartan
How the PIONEER-HF and PARADIGM-HF trials have focused on varied, but realistic heart failure patients.
Wouter Jukema, MD, PhD: PCSK9 Inhibitor Potential, Tolerability
It's been 4 years since the drug class reached the market. Are patients adhering to the therapy, and what more potential does it have?
Michael J. Reardon, MD: Long-Term TAVR Plans
What researchers from the low-risk TAVR trial anticipate they will find in their decade-long assessment.
Steven Nissen, MD: Balancing Therapy & Lifestyle in Guidelines
With cardiovascular drug classes inhibitors owning discussion, how will recent or upcoming guideline updates address their use alongside lifestyle management?
Rajan Patel, MD: Breaking New Ground in Minimally Invasive CV Care
Progress in invasive measures for cardiovascular conditions has allowed clinicians the ability to venture into new ground.
Khaldoun Tarakji, MD, MPH: Assessing, Advancing the WRAP-IT Results
What plans are held to progress the impressive findings of an envelope for cardiovascular device infection?
Adam DeVore, MD: Sacubitril/Valsartan Benefits in PIONEER-HF Extension
An extension of the study showed sacubitril/valsartan's benefit as an initial hospitalized heart failure therapy.
